Lactobacillus pentosus YN-02, product prepared from lactobacillus pentosus YN-02 and application of lactobacillus pentosus YN-02

Abstract

The invention provides lactobacillus pentosus YN-02, a product prepared from the lactobacillus pentosus YN-02 and application of the lactobacillus pentosus YN-02, and belongs to the technical field of biological medicine, the lactobacillus pentosus YN-02 is preserved in China Center for Type Culture Collection on October 22, 2024, and the preservation number is CCTCC NO.M20242300; the gene sequence of 16srRNA (Ribonucleic Acid) of the lactobacillus pentosus YN-02 is as shown in SEQ ID NO. 1. According to the lactobacillus pentosus YN-02, the product prepared from the lactobacillus pentosus YN-02 and the application of the lactobacillus pentosus YN-02, the lactobacillus pentosus YN-02 and the product, the lactobacillus pentosus YN-02, the product and the application have a remarkable effect in the aspect of resisting infection of listeria monocytogenes, salmonella enteritidis, escherichia coli, staphylococcus aureus and salmonella typhimurium.

Description

Technical Field

[0001] The present invention relates to the field of biological medicine technology, and in particular to a Lactiplantibacillus pentosus YN-02 and products and applications prepared therefrom. Background Art

[0002] Escherichia coli, as a Gram-negative short bacillus, is widely distributed in the natural environment and naturally exists in the intestines of humans and animals. Under normal circumstances, Escherichia coli in the intestine is beneficial to humans and can assist the human body in synthesizing vitamin K and some B vitamins. However, some Escherichia coli are pathogenic and can cause symptoms such as intestinal infections, diarrhea, and vomiting, and even lead to diseases such as hemorrhagic enteritis in severe infections.

[0003] Lactic acid bacteria are a group of bacteria that can metabolize carbohydrates and produce a large amount of lactic acid. They are widely distributed in nature and have diverse species. The vast majority of them are closely related to human life and are considered safe microorganisms (GRAS). Lactic acid bacteria produce a variety of natural antibacterial active substances such as bacteriocins, organic acids, diacetyl, and hydrogen peroxide during metabolism, and these substances form a probiotic group that exists in the gastrointestinal tract of animals.

[0004] The antibacterial substances produced by lactic acid bacteria not only do not damage the flavor of food but also can effectively inhibit the growth of pathogenic bacteria and spoilage bacteria, thereby extending the shelf life and storage period of food. Among these metabolites, the main role is played by bacteriocins produced by lactic acid bacteria. Bacteriocins have certain thermal stability, are easily decomposed by proteases in the human digestive tract, are non-toxic, and are not prone to generating drug resistance. Therefore, bacteriocins have broad application prospects in food storage, animal breeding, and the application of food preservatives.

[0005] However, it is worth noting that although lactic acid bacteria have shown great application potential in many fields, the research on certain specific lactic acid bacteria species is still relatively scarce. For example, Lactiplantibacillus pentosus YN-02, as a lactic acid bacteria species with potential value, its specific mechanism of action and application effects in food preservation, health promotion, etc. have not been fully explored. Summary of the Invention

[0006] The purpose of the present invention is to provide a Lactiplantibacillus pentosus YN-02 and products and applications prepared therefrom, which have a significant effect in resisting infections by Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium.

[0007] To achieve the above object, the present invention provides a Lactiplantibacillus pentosus YN-02, which was deposited at the China Center for Type Culture Collection on October 22, 2024, with the deposit number CCTCC NO.M20242300; and its Latin name is Lactiplantibacillus pentosus;

[0008] The gene sequence of the 16S rRNA of the Lactiplantibacillus pentosus YN-02 is shown in SEQ ID NO.1.

[0009] The present invention also provides a food and / or health food, beverage or medicine containing the above-mentioned Lactiplantibacillus pentosus YN-02, and the food and / or health food, beverage or medicine has the function of resisting Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, Salmonella typhimurium infection.

[0010] Preferably, the food and / or health food, beverage or medicine contains viable and / or inactivated Lactiplantibacillus pentosus YN-02, wherein the viable count of Lactiplantibacillus pentosus YN-02 is 1×10 9 CFU / mL.

[0011] The present invention also provides an application of the Lactiplantibacillus pentosus YN-02 as described above in the preparation of an antibacterial agent, and the antibacterial agent is an antibacterial agent against Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, Salmonella typhimurium.

[0012] Therefore, the present invention adopts the above-mentioned Lactiplantibacillus pentosus YN-02 and the products and applications prepared therefrom, and the beneficial technical effects are as follows:

[0013] (1) Based on Lactiplantibacillus pentosus YN-02, the present invention can develop foods and / or health foods, beverages or medicines with the function of relieving Escherichia coli infection. These products not only enrich the market choices, but also provide consumers with healthier and safer food options.

[0014] (2) Lactiplantibacillus pentosus YN-02 can regulate the intestinal flora, restore metabolic disorders, thereby improving intestinal homeostasis and enhancing the body's immune function, and has a significant effect in resisting Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, Salmonella typhimurium infection. Description of the Drawings

[0015] Figure 1 It is a phylogenetic tree diagram of Lactiplantibacillus pentosus YN-02;

[0016] Figure 2 It is the gene annotation of Lactiplantibacillus pentosus YN-02;

[0017] Figure 3 Carbohydrate-active enzyme annotation of Lactiplantibacillus pentosus YN-02

[0018] Figure 4 Antibacterial activity of Lactiplantibacillus pentosus YN-02

[0019] Figure 5 Effect of Lactiplantibacillus pentosus YN-02 on the potassium ion concentration inside and outside Escherichia coli cells

[0020] Figure 6 Effect of Lactiplantibacillus pentosus YN-02 on the protein content inside and outside Escherichia coli cells

[0021] Figure 7 Effect of Lactiplantibacillus pentosus YN-02 on the ATPase concentration of Escherichia coli

[0022] Figure 8 Effect of Lactiplantibacillus pentosus YN-02 on the intracellular and extracellular concentrations of alkaline phosphatase in Escherichia coli

[0023] Figure 9 Effect of Lactiplantibacillus pentosus YN-02 on the biofilm of Escherichia coli

[0024] Figure 10 Degree of organ degeneration and overall health diagram of mice; among them, Figure 10 (a) in it is the diagram of the mouse heart index; Figure 10 (b) in it is the diagram of the mouse lung index and spleen index; Figure 10 (c) in it is the diagram of the mouse kidney index;

[0025] Figure 11 Diagram of intestinal villus height and crypt depth; among them, Figure 11 (a) in it is the column diagram of intestinal villus height and crypt depth; Figure 11 (b) in it is the V / C diagram of the ratio of mouse intestinal villus height (V) to crypt depth (C);

[0026] Figure 12 Diagram of apoptosis and proliferation of intestinal epithelial cells; among them, Figure 12 (a) in it is the diagram of cell density and positive rate; Figure 12 (b) in it is the diagram of average optical density. Detailed implementation mode

[0027] The technical solution of the present invention will be further described below with reference to the accompanying drawings and embodiments.

[0028] Unless otherwise defined, the technical terms or scientific terms used in this invention shall have the ordinary meanings as understood by those of ordinary skill in the field to which this invention pertains.

[0029] Example 1

[0030] Isolation and screening of Lactiplantibacillus pentosus YN-02.

[0031] Collect fresh koumiss and inoculate it into MRS broth medium (solid), and culture it at 37 °C for 24 - 48 h to enrich lactic acid bacteria. Use the streak plate method to inoculate the enriched lactic acid bacteria onto MRS agar medium, culture it at 37 °C for 24 - 48 h, and pick single colonies for purification culture.

[0032] Use the Oxford cup method or paper disk method for primary screening. Spread known indicator bacteria (such as common pathogenic bacteria like Escherichia coli, Staphylococcus aureus, etc.) on the plate of MRS broth medium (solid), and then place an Oxford cup on the plate or stick a paper disk containing the culture solution of koumiss strains. After culturing for a period of time, if the koumiss strains can produce antibacterial substances, an obvious antibacterial zone will form around the Oxford cup or the paper disk. Measure the diameter of the antibacterial zone to preliminarily screen out the koumiss strains with antibacterial activity. Inoculate the strains with antibacterial activity obtained from primary screening into MRS broth medium (liquid) for fermentation culture, and collect the fermentation broth. Mix the fermentation broth with the indicator bacteria for co-culture, and measure the growth of the indicator bacteria after co-culture, such as judging the degree of inhibition of the growth of the indicator bacteria by measuring the absorbance and other methods. Compared with primary screening, secondary screening can more accurately evaluate the antibacterial ability and stability of the strains.

[0033] The formula of MRS broth medium (solid) is: 10 g of soy peptone, 5 g of beef extract, 4 g of yeast powder, 20 g of glucose, 1 mL of Tween-80, 2 g of disodium hydrogen phosphate, 5 g of anhydrous sodium acetate, 2 g of citric acid triammonium, 0.02 g of manganese sulfate, 0.1 g of magnesium sulfate, 15 g of agar powder, made up to 1 L with distilled water, adjust the initial pH to 6.20, and sterilize at 121 °C for 15 min.

[0034] The formula of MRS broth medium (liquid) is: 10 g of soy peptone, 5 g of beef extract, 4 g of yeast powder, 20 g of glucose, 1 mL of Tween-80, 2 g of disodium hydrogen phosphate, 5 g of anhydrous sodium acetate, 2 g of citric acid triammonium, 0.02 g of manganese sulfate, 0.1 g of magnesium sulfate, made up to 1 L with distilled water, adjust the initial pH to 6.20, and sterilize at 121 °C for 15 min.

[0035] Morphological observation was carried out on the antibacterial strains obtained by secondary screening, including colony morphology (such as colony size, shape, color, edge, etc.), cell morphology (observing the shape, size, arrangement mode of cells through a microscope), and comparing with the morphological characteristics of known lactic acid bacteria to preliminarily judge the category of the strains. A series of physiological and biochemical tests (common methods in this field) were carried out to further determine the physiological and biochemical characteristics of the strains and compare with the physiological and biochemical characteristic database of known lactic acid bacteria to accurately identify the species of the strains.

[0036] Molecular biology identification.

[0037] Genomic DNA of the strain was extracted, and specific gene fragments such as its 16srRNA gene were amplified by PCR technology and sequenced. The molecular sequence was compared by blastn in the NCBI database, and it was confirmed that YN-02 was Lactiplantibacillus pentosus. The phylogenetic tree of YN-02 is as Figure 1 shown.

[0038] The whole genome of Lactiplantibacillus pentosus YN-02 was sequenced using the Illumina HiSeq sequencing platform. After assembly and comparison, its genome length was 2019473bp, the G+C content was 42.31%, it contained 1 plasmid, and the chromosomal genome contained 2071 coding genes.

[0039] Testing for resistance to gastrointestinal fluids and bile salts.

[0040] The survival rate of Lactiplantibacillus pentosus at pH 2.0 was 98%. Lactiplantibacillus pentosus was placed in simulated gastric juice (pH = 2.5) and cultured at a certain temperature (37°C) for 2-4 h, and its survival rate was 96%. Then it was transferred to simulated intestinal juice (pH = 8.0) and cultured at 37°C for 3 h, and the survival rate was 92%. Lactiplantibacillus pentosus was put into a medium containing a certain concentration of bile salts (0.3%) and cultured at 37°C as well, and the survival rate was 94.5%. It shows that Lactiplantibacillus pentosus YN-02 has good resistance to gastrointestinal fluids and bile salts and can survive in the human gastrointestinal environment.

[0041] Example 2

[0042] Functional gene characteristics of Lactiplantibacillus pentosus YN-02.

[0043] The KEGG database was used to perform functional annotation on the whole genome of Lactiplantibacillus pentosus YN-02. KEGG is a professional database for comparing and analyzing bacterial genes and metabolic pathways at the molecular level, which can achieve the exploration of bacteria at the molecular level and study the relationship between functional genes and biomolecules in various biological pathways. The KEGG database classifies the biological pathways of microorganisms into six categories: Metabolism, Genetic Information Processing, Environmental Information Processing, Cellular Processes, Organismal Systems, and Human Diseases.

[0044] Figure 2 The specific annotation results are shown. Lactiplantibacillus pentosus YN-02 was annotated with 1,873 functional genes through KEGG annotation. The category with the largest functional proportion is Metabolism, and the smallest is Cellular Processes. Among them, there are 175 genes related to carbohydrate metabolism, 102 genes related to membrane transport, 76 genes related to nucleotide metabolism, and 67 genes related to the metabolism of cofactors and vitamins in the metabolic process, indicating that the strain has strong carbohydrate, nucleotide, and vitamin metabolism capabilities.

[0045] The Carbohydrate-Active Enzymes database (CAZy) is a database for comparing and annotating complex enzymes of bacteria for synthesizing or utilizing carbohydrates and other sugar substances. The CAZy database classifies carbohydrate-active enzymes into six categories: Glycoside Hydrolases (GH), Glycosyltransferases (GT), Polysaccharide Lyases (PL), Carbohydrate Esterases (CE), Carbohydrate-Binding Modules (CM), Auxiliary Activities (AA), etc. As Figure 3 shown, Lactiplantibacillus pentosus YN-02 was successfully annotated with 64 genes encoding carbohydrate-active enzymes using the CAZy database, which were divided into 4 protein families based on the amino acid sequence similarity in the encoded protein domains, including 5 Auxiliary Activities (AA) genes, 11 Carbohydrate-Binding Modules (CM) genes, 30 Glycoside Hydrolases (GH) genes, and 18 Glycosyltransferases (GT) genes.

[0046] Functional gene annotation related to tolerance of Lactiplantibacillus pentosus YN-02 was carried out, and 8 acid tolerance-related genes (glmU, ygjK, celA, celB, celC, bglA, licR, crr) were annotated; 1 bile salt tolerance-related gene (rpiU); 5 antibacterial-related genes (FabG, SrtA, rsgA, opuBD, OpuA); 3 adhesion-related genes (thiN, purD, gcvH).

[0047] Genes related to antibacterial function were detected and annotated in the genome of Lactiplantibacillus pentosus YN-02. The specific genes are shown in Table 1.

[0048] Table 1 Genes related to antibacterial function of Lactiplantibacillus pentosus YN-02

[0049]

[0050] Example 3

[0051] Antibacterial activity of Lactiplantibacillus pentosus YN-02.

[0052] Preparation of the fermentation supernatant of Lactiplantibacillus pentosus YN-02 and indicator bacteria.

[0053] Each test strain was inoculated into MRS liquid medium at a volume fraction of 2%, fermented at 37°C for 24 h, centrifuged (8000 r / min, 10 min), and the supernatant was taken, filtered through a 0.22 μm microporous filter to obtain the strain fermentation supernatant, and stored at 4°C for later use. Each bacterium used as an indicator bacterium was inoculated into LB broth medium at a volume fraction of 2%, cultured at 37°C for 24 h until the second generation, and stored at 4°C for later use. The mold was inoculated on a PDA slant medium, cultured in an incubator at 28°C for 4 d, a certain amount of sterile normal saline was added, the spores on the slant were scraped off, shaken, and then the sterile normal saline containing mold spores was filtered through sterile gauze to remove the mycelial residues, and the concentration of the spore suspension was adjusted to about 105 spores / mL, and stored at 4°C for later use.

[0054] Determination of the antibacterial activity of the fermentation supernatant of Lactiplantibacillus pentosus YN-02.

[0055] As Figure 4As shown in the figure, the antibacterial rate of Lactiplantibacillus pentosus YN-02 was determined. It had antibacterial activity against all tested strains at a concentration of 512 μM, and the antibacterial rate was higher than 90%. The antibacterial rates against Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium were 98.93%, 97.45%, 93.79%, 99.38%, and 97.35%, respectively. The experiment verified that Lactiplantibacillus pentosus YN-02 is an antibacterial strain with high antibacterial activity against a variety of bacteria, and it is considered that the antibacterial active substances in the fermentation supernatant of Lactiplantibacillus pentosus YN-02 have a wide antibacterial range, providing the possibility for future development and application.

[0056] The following illustrates the antibacterial mechanism of Lactiplantibacillus pentosus YN-02 against Escherichia coli.

[0057] (1) Effect of Lactiplantibacillus pentosus YN-02 on the cell membrane permeability of Escherichia coli.

[0058] Effect of Lactiplantibacillus pentosus YN-02 on the potassium ion concentration inside and outside the bacteria.

[0059] There is a concentration difference of potassium ions inside and outside the bacterial cells, and the permeability of the cell membrane to potassium ions is crucial for maintaining this concentration difference and the normal physiological functions of the cells. Examine the concentration of potassium ions released from Escherichia coli after treatment with Lactiplantibacillus pentosus YN-02. The results are as Figure 5 shown. The potassium ion concentration inside normal-growing Escherichia coli cells is 1.76 mg / L; after treatment with Lactiplantibacillus pentosus YN-02, the intracellular potassium ion concentration increased by 5.94 mg / L. This indicates that Lactiplantibacillus pentosus YN-02 increased the cell membrane permeability of Escherichia coli, resulting in more potassium ions being released from the cells.

[0060] Effect of Lactiplantibacillus pentosus YN-02 on the protein content inside and outside the bacteria.

[0061] Changes in the protein content inside and outside the bacteria can reflect the growth state and environmental adaptability of the bacteria. If the protein content inside the bacteria decreases, this may mean that the growth and reproduction of the bacteria are inhibited, or the proteins produced by the bacteria are consumed or degraded by other organisms or environmental factors. As Figure 6 shown, the intracellular protein concentrations of normal-growing Escherichia coli and treated Escherichia coli are 4.42 and 3.08 mg / mL, respectively, accounting for 72% and 56% of the total content; the concentrations of leaked proteins in the supernatant of the control group and treated Escherichia coli are 1.64 and 2.44 mg / mL, respectively, accounting for 28% and 34% of the total content. These results indicate that after treatment with Lactiplantibacillus pentosus YN-02, the cell membrane was damaged, and a large amount of protein leaked out of the bacterial cells.

[0062] (2) Effects of Lactiplantibacillus pentosus YN-02 on bacterial metabolic enzymes.

[0063] Effects of Lactiplantibacillus pentosus YN-02 on the concentration of bacterial ATPase.

[0064] ATPase is mainly involved in energy conversion and ion transport and is a key enzyme for energy production in bacteria. When cells are damaged or die, the ATP content in the bacterial cells will rapidly decline. Therefore, the ATP content can reflect the survival state of the cells. As Figure 7 can be seen, compared with the control group, the ATPase concentration of Escherichia coli treated with Lactiplantibacillus pentosus YN-02 decreased gradually and significantly (p < 0.05). This may mean that YN-02 has an impact on the energy metabolism of bacteria, affects the life activities of bacteria, and then inhibits or kills bacteria. Therefore, Lactiplantibacillus pentosus YN-02 can inhibit the expression activity of ATPase in bacterial cells.

[0065] Effects of Lactiplantibacillus pentosus YN-02 on bacterial alkaline phosphatase.

[0066] Alkaline phosphatase plays an important role in physiological processes such as energy metabolism, cell wall synthesis, and material transport in bacteria. As Figure 8 can be seen, compared with the Escherichia coli control group, after treatment with Lactiplantibacillus pentosus YN-02, the percentage of intracellular alkaline enzyme decreased significantly from 84% to 14%, and the percentage of extracellular alkaline enzyme increased significantly from 16% to 86%. This indicates that Lactiplantibacillus pentosus YN-02 can inhibit the expression activity of alkaline phosphatase in bacterial cells.

[0067] (3) Effects of Lactiplantibacillus pentosus YN-02 on bacterial biofilm formation.

[0068] As Figure 9 can be seen, the inhibition rate of Lactiplantibacillus pentosus YN-02 on the immature biofilm of Escherichia coli reached 88.4%. This indicates that Lactiplantibacillus pentosus YN-02 can play an effective inhibitory role at the early stage of bacterial biofilm formation, thus preventing the further development of the biofilm. For mature biofilms, Lactiplantibacillus pentosus YN-02 also showed strong inhibitory ability. Its inhibition rate on the mature biofilm of Escherichia coli was as high as 94.6%. This shows that Lactiplantibacillus pentosus YN-02 can not only prevent the formation of biofilms, but also effectively destroy the already formed biofilms, showing its potential application value in anti-biofilm therapy.

[0069] Therefore, Lactiplantibacillus pentosus YN-02 inhibits the formation of Escherichia coli biofilms by disrupting the integrity of the Escherichia coli cell membrane, enhancing cell membrane permeability, affecting proteins and potassium ions inside and outside the cell, and changing the content and activity of metabolic enzymes such as ATPase and alkaline phosphatase, ultimately achieving efficient bactericidal effect on Escherichia coli.

[0070] Example 4

[0071] Therapeutic effect of Lactiplantibacillus pentosus YN-02 on mice infected with Escherichia coli.

[0072] Experimental method: In this example, changes in mouse body weight, survival rate, food intake, etc. were observed. The health status of mice could be preliminarily evaluated through these clinical symptoms and changes in growth indicators. Subsequently, the effects of Lactiplantibacillus pentosus YN-02 on the immune system and antioxidant system of mice were quantified by measuring blood cytokines and antioxidant capacity of mice. Then, the effects on intestinal pathological changes were judged by HE staining and apoptosis detection of intestinal tissues, directly reflecting the therapeutic effect of Lactiplantibacillus pentosus YN-02 on intestinal inflammation and injury. Finally, the analysis of intestinal microbiota and metabolomics could reveal the effects of Lactiplantibacillus pentosus YN-02 on intestinal microbiota, metabolites and metabolic pathways of mice. Among them, the blank control group (CON, gavaged with 0.2 mL of normal saline), Escherichia coli model group (MOD, gavaged with 1×10 8 CFU of Escherichia coli), Lactiplantibacillus pentosus YN-02 treatment group (TMT, gavaged with 1×10 8 CFU of Escherichia coli + gavaged with 1×10 8 CFU of Lactiplantibacillus pentosus YN-02 powder), Lactiplantibacillus pentosus YN-02 control group (PET, gavaged with 1×10 8 CFU of Lactiplantibacillus pentosus YN-02 powder).

[0073] Effect of Lactiplantibacillus pentosus YN-02 on organ coefficients of mice infected with Escherichia coli.

[0074] The degree of organ degeneration and overall health status of mice can be evaluated through mouse organ coefficients. As Figure 10 can be seen, the heart indices of the MOD and TMT groups were lower than those of the CON group (p < 0.05), but the spleen index, kidney index, liver index, and lung index were higher. Comparing the data of the MOD and TMT groups, the differences between the two groups were significant, especially the spleen index and heart index. In summary, Lactiplantibacillus pentosus YN-02 is helpful for restoring the healthy status of mouse organ functions.

[0075] Effect of Lactiplantibacillus pentosus YN-02 on improving intestinal function of mice infected with Escherichia coli.

[0076] Intestinal villus height and crypt depth are important indicators reflecting the intestinal function state. The V / C ratio is calculated based on the intestinal villus height (V) and crypt depth (C) of mice. As Figure 11 shown, the villus height of the CON group was significantly higher than that of the MOD and TMT groups (p < 0.05), and the villus height of the TMT group was higher than that of the MOD group. There was no significant difference in the crypt depth among the mice in each group. For the ratio V / C of the villus height (V) and crypt depth (C), the value of the CON group was the highest, followed by the TMT group, and then the MOD group. In summary, Lactiplantibacillus pentosus YN-02 can repair the intestinal mucosa damaged by Escherichia coli and enhance the digestion and absorption function of mice.

[0077] Improvement effect of Lactiplantibacillus pentosus YN-02 on apoptosis of intestinal cells in mice infected with Escherichia coli.

[0078] The key factors maintaining intestinal homeostasis are the apoptosis and proliferation of intestinal epithelial cells. As shown in Figure 12 the results, the positive rate of the MOD group was the highest, the number of apoptotic cells was the largest, and the cell density was the largest. Therefore, there were a large number of apoptotic cells in a large area in the mouse colon epithelial tissue. Followed by the CON group and the TMT group, the number of apoptotic cells was significantly reduced compared with the MOD group. Finally, the PEP group had a positive rate of 0.35%, indicating that there were no obvious apoptotic cell characteristics in the mouse colon epithelial tissue. In summary, it is speculated that Lactiplantibacillus pentosus YN-02 can improve intestinal function by inhibiting epithelial cell apoptosis.

[0079] Experimental results: The therapeutic effect of Lactiplantibacillus pentosus YN-02 on mice infected with Escherichia coli and its antibacterial mechanism in vivo were deeply studied through animal experiments. The mice were divided into four groups in the experiment, including blank control, Escherichia coli infection, Lactiplantibacillus pentosus YN-02 intervention, and single-bacterium control. The experimental results showed that Escherichia coli infection led to listlessness, decreased appetite, weight loss in mice, and changed organ indices, while intragastric administration of Lactiplantibacillus pentosus YN-02 effectively alleviated these symptoms and restored the normal state of mice. In addition, Lactiplantibacillus pentosus YN-02 also promoted intestinal villus growth, reduced apoptosis, and alleviated intestinal damage. Lactiplantibacillus pentosus YN-02 restored the metabolic disorders caused by Escherichia coli infection by regulating the flora. Therefore, Lactiplantibacillus pentosus YN-02 has a significant protective effect on mice infected with Escherichia coli.

[0080] Therefore, the present invention adopts the above-mentioned Lactiplantibacillus pentosus YN-02 and products and applications prepared therefrom, which have significant effects against Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium.

[0081] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit them. Although the present invention has been described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that they can still modify the technical solutions of the present invention or make equivalent replacements, and these modifications or equivalent replacements cannot make the modified technical solutions deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. A lactobacillus pentosus YN-02, characterized in that The Lactobacillus pentosus YN-02 was deposited in the China Center for Type Culture Collection on October 22, 2024, with a deposit number of CCTCC NO.M20242300; its Latin name is Lactiplantibacillus pentosus; The gene sequence of 16srRNA of the Lactobacillus pentosus YN-02 is shown in SEQ ID NO.

1.

2. A food and / or health food, beverage or medicine comprising the Lactobacillus pentosus YN-02 according to claim 1, characterized in that: The food and / or health food, beverage or medicine has the function of resisting infection by Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus and Salmonella typhimurium.

3. A food and / or health food, beverage or medicine containing Lactobacillus pentosus YN-02 according to claim 2, characterized in that: The food and / or health food, beverage or medicine contains live and / or inactivated bacteria of Lactobacillus pentosus YN-02, wherein the number of live bacteria of Lactobacillus pentosus YN-02 is not less than 1×10 9 CFU / mL.

4. A use of the lactobacillus pentosus YN-02 according to claim 1 in the preparation of an antibacterial agent, characterized in that: The antibacterial agent is an antibacterial agent against Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus and Salmonella typhimurium.

Images